Arseniy Goncharov

Arseniy Goncharov

Auto-generated profile, based on publicly available information

Arseniy Goncharov

Department for General and Interventional Cardiology/Angiology, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany (A.G., T.K.R., K.P.F., M.P., V.R., M.G.).

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2023 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
VDVarius Dannenberg
Varius Dannenberg
PBPhilipp E. Bartko
Philipp E. Bartko
MAMartin Andreas
Martin Andreas
ABAnna Bartunek
Anna Bartunek
AGArseniy Goncharov
Arseniy Goncharov
MIMaria Ivannikova
Maria Ivannikova
Transcatheter tricuspid edge-to-edge repair (T-TEER) has gained widespread use for the treatment of tricuspid regurgitation (TR) in symptomatic patients with high operative risk. Although secondary TR is the most common pathology, some patients exhibit primary or predominantly primary TR. Characterization of patients with these pathologies in the T-TEER context has not been systematically performed. Patients assigned to T-TEER by the interdisciplinary heart team were consecutively recruited in two European centres over 4 years. Echocardiographic images were evaluated to distinguish between primary and secondary causes of TR. Both groups were compared concerning procedural results. A total of 339 patients were recruited, 13% with primary TR and 87% with secondary TR. Patients with primary TR had a smaller right ventricle (basal diameter 45 vs. 49 mm, P = 0.004), a better right ventricular function (fractional area change 45 vs. 41%, P = 0.001), a smaller right (28 vs. 34 cm2, P = 0.021) and left (52 vs. 67 mL/m2, P = 0.038) atrium, and a better left ventricular ejection fraction (60 vs. 52%, P = 0.005). The severity of TR was similar in primary and secondary TR at baseline (TR vena contracta width pre-interventional 13 ± 4 vs. 14 ± 5 mm, P = 0.19), and T-TEER significantly reduced TR in both groups (TR vena contracta width post-interventional 4 ± 3 vs. 5 ± 5 mm, P = 0.10). These findings remained stable after propensity score matching. Complications were similar between both groups. T-TEER confers equally safe and effective reduction of TR in patients with primary and secondary TR. Edge-to-edge repair in patients with primary tricuspid regurgitation. TR, tricuspid regurgitation.

1 June 2023 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
AGArseniy Goncharov
Arseniy Goncharov
HFHenrik Fox
Henrik Fox
SBSabine Bleiziffer
Sabine Bleiziffer
TRTanja Rudolph
Tanja Rudolph
Background: Up to 30% of patients with the left ventricular assist device (LVAD) develop moderate to severe aortic regurgitation (AR) within the first year. Surgical aortic valve replacement (SAVR) is the treatment of choice in patients with native AR. However, the high perioperative risk in patients with LVAD might prohibit surgery and choice of therapy is challenging.Case summary: We report on a 55-year-old female patient with a severe AR 15 months after implantation of LVAD due to advanced heart failure (HF) as a consequence of ischaemic cardiomyopathy. Surgical aortic valve replacement was discarded due to high surgical risk. Thus, the decision was made to evaluate a transcatheter aortic valve replacement (TAVR) with the TrilogyXTä prothesis (JenaValve Technology, Inc., CA, USA). Echocardiographic and fluoroscopic control showed an optimal valve position with no evidence of valvular or paravalvular regurgitation. The patient was discharged 6 days later in a good general condition. At the 3-month follow-up, the patient showed noteworthy symptomatic improvement with no sign of HF.Discussion: Aortic regurgitation is a common complication among advanced HF patients treated with LVADSystems and associated with a deterioration in the quality of life and worsen clinical prognosis. The treatment options are limited to percutaneous occluder devices, SAVR, off-label TAVR, and heart transplantation. With the approval of the TrilogyXT JenaValve system, a novel dedicated TF-TAVR option is now available. Our experience demonstrates the technical feasibility and safety of this system in patients with LVAD and AR resulting in effective elimination of AR.

6 November 2024 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
MGMuhammed Gerçek
Muhammed Gerçek
MIMaria Ivannikova
Maria Ivannikova
MGMustafa Gerçek
Mustafa Gerçek
MMMaximilian Mörsdorf
Maximilian Mörsdorf
JKJohannes Kirchner
Johannes Kirchner
DDDaniel Dumitrescu
Daniel Dumitrescu
Transcatheter mitral valve interventions (TMVI) has been proven to reduce symptom burden and improve outcome in patients with severe mitral regurgitation (MR). However, the impact of right ventricular function (RVF) on exercise capacity in MR patients is less well understood. Cardiopulmonary exercise testing (CPET) is the most comprehensive approach to assess maximum exercise capacity. Submaximal exercise capacity (SEC), assessed by constant work rate exercise time testing (CWRET), is presumed to be relevant in daily life activities, and gives a more differentiated physiological insight into the nature of exercise intolerance. Thus, 28 MR patients underwent CPET and CWRET (at 75% of maximum work rate in the initial incremental exercise test) prior to TMVI and 3-months post-procedurally. Patients´ mean age was 75.0±8.7 years and 32.1% were female. One patient presented with a MR reduction of less than 2 grades. RVF was at least moderately impaired in 25% of the patients. SEC of these patients was lower, but did not significantly differ (416.4s±359.6 vs. 296.1±216.5s; p=) from patients without RVF-deterioration. At follow up, the SEC improved significantly (from 337.4±262.2s to 517.4±393.5s; p=0.006). Maximum oxygen uptake (peakVO2) showed a positive trend, but no statistically significant difference (10.3±3.1ml/min/kg vs. 11.3±3.4ml/min/kg; p=0.06). RVF improved in 35.7% of the patients and these patients showed a significantly higher SEC increase (471.7±153.9s vs. 82.7±47.0s, p=0.003). SEC is significantly increased in MR patients undergoing TMVI, reflecting an improvement especially regarding daily life activities. This may be related to TMVI´s beneficial effect on right ventricular remodeling.

5 May 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
FRFelix Rudolph
Felix Rudolph
AGArseniy Goncharov
Arseniy Goncharov
ANAkhil Narang
Akhil Narang
MKMaria L. Körber
Maria L. Körber
JPJyothy J. Puthumana
Jyothy J. Puthumana
MGMuhammed Gerçek
Muhammed Gerçek
BACKGROUND: Observational registries have shown improved survival among patients with severe or greater tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve repair (TTVr) compared with conservative management. However, it remains unclear whether this survival benefit persists when specifically comparing patients undergoing TTVr with those who screen failed. METHODS: We conducted a retrospective analysis of 547 patients from the TriSelect registry evaluated for TTVr—either transcatheter tricuspid valve edge-to-edge repair or direct transcatheter tricuspid valve annuloplasty at 3 tertiary centers in the United States and Germany between 2016 and 2021. The end point of 1-year survival was stratified by treatment group (TTVr versus screen fail) and procedural success (residual TR ≤ moderate versus > moderate). RESULTS: Of the 547 patients, 219 (41.9%) screen failed and 318 (58.1%) underwent TTVr (transcatheter tricuspid valve edge-to-edge repair, 61.6%; transcatheter tricuspid valve annuloplasty, 38.4%). Among treated patients, 224 (70.4%) achieved residual TR ≤ moderate. Unadjusted Kaplan-Meier–derived 1-year survival was significantly higher in patients who underwent TTVr compared with screen-fail patients (82.5% versus 68.4%, log-rank P moderate, there was no survival benefit compared with screen-fail patients (unadjusted log-rank P =0.74). CONCLUSIONS: In this registry-based analysis, TTVr was associated with improved 1-year survival compared with screen-fail patients, but only when TR was reduced to moderate or less. These findings highlight the critical importance of achieving procedural success with a TTVr along with early referral and transcatheter tricuspid valve intervention device selection.